Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

PROK vs EVMN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EVMN Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 3–4 Matrix Metrics)

EVMN Overall Winner 6-Pillar Tally: PROK 1 – 3 EVMN (2 Tie) Matrix Metrics: PROK 4 – 3 EVMN

As of Nov 16, 2026, Evommune, Inc. (EVMN) is the stronger overall head-to-head candidate over ProKidney Corp. Class A (PROK) in the Tradestie Institutional Equity Comparison Engine, winning 3–4 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). PROK carries a Unified Composite Score of 54.0/100 (HOLD) at $1.04 (N/M Forward P/E, -24830.3% operating margin), whereas EVMN carries 30.0/100 (SELL) at $7.10 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While PROK currently prints a higher short-term Unified Composite Score (54.0/100 HOLD vs. EVMN 30.0/100 SELL), EVMN captures the overall institutional head-to-head verdict (3–4 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -24830.3% operating margin) and revenue trajectory (+0.0% vs. -19.8% YoY).
  • Technical & Structure Timing Caution: PROK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.5); meanwhile EVMN trades in a Neutral technical trend (SURGE options phase, RSI 52.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PROK vs EVMN
PROK NASDAQ
ProKidney Corp. Class A Ordinary Shares
Biological Products, (No Disgnostic Substances)
$1.04
-0.48% 1D
Market Cap $415.2M
TTM Revenue $775,000
Forward P/E N/M
Beta / 30D Vol 1.68β · 92% Vol
Unified Composite Score
54.0 / 100 HOLD
Tech 33.0 Fund 65.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.7%), weak momentum, RSI 33
RSI-14: 32.5 · SMA20: $1.25 · SMA50: $1.51
EVMN US Equity Head-to-Head Winner
Evommune, Inc.
Pharmaceutical Preparations
$7.10
-6.95% 1D
Market Cap $291.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.05β · 118% Vol
Unified Composite Score
30.0 / 100 SELL
Tech 50.0 Fund 35.0 Flow 69.0 Mom 44.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 52.2 · SMA20: $6.45 · SMA50: $7.47

6-Pillar Scorecard Institutional Category Breakdown (PROK 1 – 3 EVMN)

Columns: Metric · PROK · EVMN
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale PROK
Revenue Growth (YoY) -19.8% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $775,000 N/A
Market Cap $415.2M $291.1M
3. Profitability & Quality EVMN
Gross Margin 100.0% N/A
Operating Margin -24830.3% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -73.4% -69.5%
4. Balance Sheet & Cash Flow EVMN
Cash Generation (TTM) -$160M -$75M
Cash Flow Margin N/A N/A
Net Cash / Leverage $71M Net Cash $52M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EVMN
Options Structure Phase BREAKDOWN SURGE
Current IV / %ile 364.9% (42nd %ile) 209.0% (53rd %ile)
Put/Call OI Skew 0.83x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Markdown ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PROK (4) vs EVMN (3)
Institutional Metric PROK EVMN Criterion Row Edge
Market Capitalization
Scale
$415.2M $291.1M Larger Scale PROK
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-19.8% +0.0% Higher Growth EVMN
Operating Margin (TTM)
Profitability
-24830.3% 0.0% Higher Margin EVMN
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-73.4% -69.5% Higher ROE EVMN
52-Week Range Position
Momentum
10% ($1–$3) 8% ($5–$33) Stronger Trend PROK
Beta / 30D Volatility
Risk Regime
1.68β · 92% Vol 1.05β · 118% Vol Lower Realized Risk PROK
Unified Institutional Score
Composite Signal
54.0 / 100 (HOLD) 30.0 / 100 (SELL) Higher Composite PROK
Trailing 12M Revenue (USD)
Operating Scale
$775,000 N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$160M ($71M Net Cash) -$75M ($52M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EVMN +59.13 pp
PROK: -21.8% · EVMN: +37.33%
3M Horizon PROK +25.43 pp
PROK: -24.64% · EVMN: -50.07%
6M Horizon PROK +32.17 pp
PROK: -35.4% · EVMN: -67.57%
1Y Horizon PROK +6.64 pp
PROK: -54.39% · EVMN: -61.03%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period PROK Revenue EVMN Revenue PROK Op. Margin EVMN Op. Margin Margin Leader
FY2024 $0M $10M -241678.9% -1000.2% EVMN
FY2025 $0M $10M -18477.8% -623.6% EVMN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PROK BREAKDOWN
50d in phase · OBV ACCUMULATION
Current IV 364.9%
IV Percentile 42nd %ile
Put/Call OI Skew 0.83x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact PROK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EVMN SURGE
5d in phase · OBV ACCUMULATION
Current IV 209.0%
IV Percentile 53rd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact EVMN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PROK Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $415.2M market capitalization and -24830.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
EVMN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $291.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PROK vs EVMN Key Questions & Quantitative Answers

As of Nov 16, 2026, Evommune, Inc. (EVMN) is the stronger overall head-to-head candidate over ProKidney Corp. Class A (PROK) in the Tradestie Institutional Equity Comparison Engine, winning 3–4 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). PROK carries a Unified Composite Score of 54.0/100 (HOLD) at $1.04 (N/M Forward P/E, -24830.3% operating margin), whereas EVMN carries 30.0/100 (SELL) at $7.10 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While PROK currently prints a higher short-term Unified Composite Score (54.0/100 HOLD vs. EVMN 30.0/100 SELL), EVMN captures the overall institutional head-to-head verdict (3–4 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -24830.3% operating margin) and revenue trajectory (+0.0% vs. -19.8% YoY). Technical & Structure Timing Caution: PROK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.5); meanwhile EVMN trades in a Neutral technical trend (SURGE options phase, RSI 52.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PROK leads the Growth & Scale pillar: PROK posts -19.8% YoY revenue growth and +0.0% YoY earnings growth on $775,000 TTM revenue (100.0% gross margin, -24830.3% operating margin), compared with EVMN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 2-period historical trajectory (FY2024 to FY2025), PROK cumulative revenue shifted N/A while EVMN shifted +0.0%. In operating R&D and SG&A reinvestment, PROK deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EVMN.

PROK and EVMN trade at balanced relative valuation multiples. PROK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas EVMN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PROK (-73.4% ROE) versus EVMN (-69.5% ROE) capital efficiency.

In options market volatility and institutional positioning, PROK carries 364.9% implied volatility (42nd %ile, Balanced (25th–60th %ile)), a 0.83x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.68β · 92% Vol realized risk). By comparison, EVMN carries 209.0% implied volatility (53rd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (1.05β · 118% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.